-

01:25:34 PM

KPRX Stock News

KPRX - Kiora Pharmaceuticals Inc

09/21/23 7:00 AM

Nasdaq : KPRX

managementlow float

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as a director, as its new Chairman. Dr. Tyle succeeds current Chairman Paul Chaney who is retiring

RHEA-AI

very positive

09/18/23 7:00 AM

Nasdaq : KPRX

clinical triallow float

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the completion of the final patient's last endpoint evaluation from the ABACUS study of KIO-301. KIO-301 is A molecular photoswitch being evaluated in a Phase 1B clinical trial for

RHEA-AI

neutral

09/14/23 7:01 AM

Nasdaq : KPRX

conferencesclinical triallow float

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from the ABACUS study of KIO-301 in patients with late-stage retinitis pigmentosa will be presented at the American Academy of Ophthalmology

RHEA-AI

neutral

09/01/23 7:00 AM

Nasdaq : KPRX

low float

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that the Company's Special Meeting of Stockholders (the "Special Meeting") held on August 31, 2023 at 9:00 a.m. Pacific Time was convened and adjourned,

RHEA-AI

neutral

08/29/23 1:43 PM

Nasdaq : KPRX

conferenceslow float

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

Kiora Pharmaceuticals (NASDAQ: KPRX) invites you to participate in a webinar highlighting the progress of molecular photoswitches in retinitis pigmentosa and the future

RHEA-AI

positive

08/23/23 7:00 AM

Nasdaq : KPRX

low float

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and European Patents covering local ocular delivery of the KIO-100 family of non-steroidal,

RHEA-AI

positive

08/22/23 1:06 PM

Nasdaq : KPRX

low float

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies for the treatment of ophthalmic diseases, today announced it has partnered with B2i Digital, Inc. to execute a comprehensive

RHEA-AI

neutral

08/16/23 7:00 AM

Nasdaq : KPRX

low float

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Kiora Pharmaceuticals (NASDAQ: KPRX) welcomes investors to watch the Company's online presentation from the H.C. Wainwright 3 rd Annual Ophthalmology Virtual Conference. As part of the talk, Kiora President & CEO Brian Strem, Ph.D.,

RHEA-AI

neutral

08/08/23 7:00 AM

Nasdaq : KPRX

earningsclinical triallow float

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concept of KIO-301 in the Ongoing Phase 1 Study in Retinitis Pigmentosa Supporting Advancement to Planned Higher Doses with Full Topline Results Expected in Q4 2023 Data Supports Hypothesized Mechanism of Action of

RHEA-AI

positive

08/03/23 7:00 AM

Nasdaq : KPRX

partnershiplow float

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage ophthalmic pharmaceutical company developing novel therapeutics for patients with high unmet needs, and the Choroideremia Research Foundation (CRF), the largest organization in

RHEA-AI

positive

KPRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttp://www.eyegatepharma.com/
Security nameKiora Pharmaceuticals Inc
SectorManufacturing
CountryUnited States

About Kiora Pharmaceuticals Inc

traded on nasdaq capital market, stock symbol eyeg, eyegate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“cmha-s”), a modified form of the natural polymer hyaluronic acid (“ha”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. our first cmha-s-based product candidate, the eyegate ocular bandage gel (“obg”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“prk”) surgery. our initial product candidate from our second platform is egp-437, incorporates a reformulated topically active corticosteroid, dexamethasone